Business Description
Tandem Diabetes Care Inc
NAICS : 339112
SIC : 3841
ISIN : US8753722037
Description
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.99 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 2 | |||||
| Debt-to-EBITDA | -4.72 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.29 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.1 | |||||
| 3-Year EBITDA Growth Rate | -138.3 | |||||
| 3-Year EPS without NRI Growth Rate | -103.1 | |||||
| 3-Year FCF Growth Rate | -117.4 | |||||
| 3-Year Book Growth Rate | -6.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 33.24 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 14.13 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.76 | |||||
| 9-Day RSI | 36.49 | |||||
| 14-Day RSI | 36.65 | |||||
| 6-1 Month Momentum % | -17.27 | |||||
| 12-1 Month Momentum % | 154.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.9 | |||||
| Quick Ratio | 2.32 | |||||
| Cash Ratio | 1.83 | |||||
| Days Inventory | 130.95 | |||||
| Days Sales Outstanding | 43.08 | |||||
| Days Payable | 40.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.7 | |||||
| Shareholder Yield % | -0.57 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.79 | |||||
| Operating Margin % | -15.64 | |||||
| Net Margin % | -14.84 | |||||
| FCF Margin % | -4.44 | |||||
| ROE % | -47.23 | |||||
| ROA % | -13.41 | |||||
| ROIC % | -33.28 | |||||
| 3-Year ROIIC % | -69.58 | |||||
| ROC (Joel Greenblatt) % | -45.34 | |||||
| ROCE % | -16.04 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.4 | |||||
| PB Ratio | 8.66 | |||||
| Price-to-Tangible-Book | 8.65 | |||||
| Price-to-Operating-Cash-Flow | 326.56 | |||||
| EV-to-EBIT | -17.59 | |||||
| EV-to-Forward-EBIT | -34.03 | |||||
| EV-to-EBITDA | -20.45 | |||||
| EV-to-Forward-EBITDA | 148.34 | |||||
| EV-to-Revenue | 2.41 | |||||
| EV-to-Forward-Revenue | 2.05 | |||||
| EV-to-FCF | -55.19 | |||||
| Price-to-Projected-FCF | 7.67 | |||||
| Price-to-Median-PS-Value | 0.58 | |||||
| Price-to-Net-Current-Asset-Value | 63.37 | |||||
| Earnings Yield (Greenblatt) % | -5.69 | |||||
| FCF Yield % | -1.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tandem Diabetes Care Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 782.774 | ||
| EPS (TTM) (€) | -1.772 | ||
| Beta | 3.1 | ||
| Volatility % | 89.37 | ||
| 14-Day RSI | 36.65 | ||
| 14-Day ATR (€) | 1.076775 | ||
| 20-Day SMA (€) | 30.9345 | ||
| 12-1 Month Momentum % | 154.97 | ||
| 52-Week Range (€) | 14.08 - 48.96 | ||
| Shares Outstanding (Mil) | 65.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tandem Diabetes Care Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tandem Diabetes Care Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tandem Diabetes Care Inc Frequently Asked Questions
What is Tandem Diabetes Care Inc(STU:TD5A)'s stock price today?
The current price of STU:TD5A is €29.15. The 52 week high of STU:TD5A is €48.96 and 52 week low is €14.08.
When is next earnings date of Tandem Diabetes Care Inc(STU:TD5A)?
The next earnings date of Tandem Diabetes Care Inc(STU:TD5A) is 2025-02-21 Est..
Does Tandem Diabetes Care Inc(STU:TD5A) pay dividends? If so, how much?
Tandem Diabetes Care Inc(STU:TD5A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers